antivirals

MYPI1999000158A0Inactive Publication Date: 1999-07-16MEDIVIR AB
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI1999000158
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
1998-01-16
Filing Date
1999-01-15
Publication Date
1999-07-16
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current HIV reverse transcriptase inhibitors have limitations in efficacy and specificity, leading to potential drug resistance and side effects, necessitating the development of novel compounds with improved antiviral activity.

Method used

Development of novel compounds and pharmaceutical compositions that target HIV reverse transcriptase, specifically designed to inhibit the virus with enhanced specificity and reduced toxicity, thereby overcoming existing limitations.

Benefits of technology

The novel compounds demonstrate increased antiviral activity and reduced toxicity, potentially leading to more effective HIV treatment with lower risks of drug resistance.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

COMPOUNDS OF THE FORMULA 1 : WHEREIN RX IS CYANO OR BROMO;R1 IS HALO;R2 IS C1-C3 ALKYL,AND PHARMACEUTICALLY ACCEPTABLE SALTS AND PRODRUGS THEREOF HAVE ACTIVITY AS ANTIRETROVIRALS.THE MOST ILLUSTRATIVE DRAWING IS (FIGURE 1)
Need to check novelty before this filing date? Find Prior Art

Description

Technical FieldThis invention relates to the held of antivirals and in particular to HIV reverse 5 transcriptase inhibitors. The invention provides novel compounds, pharmaceutical compositions comprising these compounds and methods for the inhibition of HIV employing them.

Claims

1. A compound of the formula I: wherein R* is cyano or bromo; R1 is halo; R2 is Cj-Cs alkyl, or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1, wherein R1 is fluoro.

3. A compound according to claim 1 wherein R is ethyl.

4. A compound according to claim 1, comprising at least 60% 1S,2S enantiomeric form.

5. A compound according to claim 1, wherein R* is cyano.

6. A compound according to claim 1, wherein the prodrug has the formula II: wherein R\ R1 and R2 are as defined above, ΊΟ R3 is H, (CHm)„NR5R6; R4 is H, C,-C3 alkyl, (CH,„)„NR5R6, (CHm)„C(=O)R5, (CHm)„OH, OR7, halo, CF3 or CN; R5 is H, C1-C3 alkyl, C(=O)R7; 5 R6 is H, C1-C3 alkyl; or R7 is H, C,-C|2 alkyl, (CHm)nNR5R6; X and its encompassing circle represent a ring selected from the group consisting of naphthyl, pyridyl, quinolyl or phenyl; m is independently 1 or 2; 10 n is independently 0, 1 or 2; p is 0 or 1; or a pharmaceutically acceptable salts thereof.

7. A compound according to claim 6, wherein the X-containing ring is phenyl.

8. A compound according to claim 6, wherein the X-containing ring is selected 15 from pyrid-2-yl or pyrid-3-yl.

9. A compound according to claim 6, wherein R3 is selected from the group consisting of-NH2, -NHCH3, -NHCH2CH3 or -N(CH3)2.

10. A compound according to claim 6 wherein R3 is in the meta position relative to the carbonyl group. 2011. A compound according to claim 6 wherein -(CH2O)pt and / or 4CH2) n- are absent, that is p or n are12. A compound according to claim 6, wherein R* is cyano.

13. A compound according to claim 6, wherein Rl is fluoro.

14. A compound according to claim 6, wherein R2 is ethyl. 2515. A compound according to claim 6, comprising at least 60 % J S,2S enantiomeric form.

16. A compound according to claim 1, selected from the group consisting of 24 Use of a compound according to any one of claims 1 or 6 in the manufacture of a medicament for the treatment or prophylaxis of HIV.

25. A method for the preparation of a compound of the Formula I comprising the comprising the Curtius rearrangement of the azide of a compound of the formula: followed by coupling with a compound of the formula KiH' and deprotection, wherein R1, R2 and R* are as defined above and PG is an hydroxyprotecting group.

26. A method according to claim 25, further comprising the step of a) acylating with an activated compound of the formula III: (CHtlr R* where R3, R4, X and n are as defined above but are optionally protected, and R8 is hydrogen or a conventional activating group; or b) alkylating with a compound of the formula Ilia; R’ I where n, R3, R4 and X are as defined above, but where exposed amine, hydroxy etc substituents are protected with conventional protecting groups. 5 27. The compound according to claim 10, wherein said X-containing ring is phenyl.

28. The compound according to claim 6, wherein said R1 is in the para position. 10 29. The compound according to claim I, comprising at least 90% 1S, 2S enantiomeric form.

30. The compound according to claim 6, comprising at least 90% 1 S,2S enantiometric form. 31 The compound according to claim 6, wherein the X-containing ring is a pyrid-3-yl. weeks FIGURE I 240 FIGURE 2 I Relative 3 / 3 RU / ((9fmol) x RU) x 10e7 _ _________